✦ LIBER ✦

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

✍ Scribed by Letendre, Louis ;Niedringhaus, Robert D. ;Therneau, Terry M. ;Gastineau, Dennis A. ;Goldberg, Richard M. ;Gerstner, James B. ;Mailliard, James A. ;Gundlach, William J. ;Kardinal, Carl G. ;Pierre, Robert V.

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 362 KB
Volume: 17
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950170202

No coin nor oath required. For personal study only.

✦ Synopsis

Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients.

Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6-month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.

📜 SIMILAR VOLUMES

Low-dose cytosine arabinoside treatment

Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients

✍ Herve Tilly; Sylvie Castaigne; Dominique Bordessoule; Francois Sigaux; Marie-thé 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Treatment of childhood acute lymphoblast

Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin

✍ Ishii, Eiichi ;Hara, Toshiro ;Ohkubo, Kenshi ;Matsuzaki, Akinobu ;Takeuchi, Taka 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

Intermediate-dose cytosine arabinoside a

Intermediate-dose cytosine arabinoside and amsacrine an effective regimen with low toxicity in refractory acute nonlymphocytic leukemia

✍ Adriaan W. Dekker; H. Karel NieuwenhuisKarel; Leo F. Verdonck 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB 👁 2 views

High-dose cytosine arabinoside in the tr

High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens

✍ Herzig, Roger H. ;Herzig, Geoffrey P. ;Lazarus, Hillard M. ;Wolff, Steven N. ;Ph 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

High-dose cytosine arabinoside (Ara-C) was used in adult patients with refractory acute nonlymphoblastic leukemia, either alone (3 g/m2 every 12 h X 12 doses) or with 3 additional days of anthracycline antibiotics. The systemic toxicities were similar for both groups without an increase in the group

Acute polyneuropathy after high dose cyt

Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia

✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo